[go: up one dir, main page]

JP2018172409A5 - 15−hepeを含む組成物および同組成物を使用する方法 - Google Patents

15−hepeを含む組成物および同組成物を使用する方法 Download PDF

Info

Publication number
JP2018172409A5
JP2018172409A5 JP2018121494A JP2018121494A JP2018172409A5 JP 2018172409 A5 JP2018172409 A5 JP 2018172409A5 JP 2018121494 A JP2018121494 A JP 2018121494A JP 2018121494 A JP2018121494 A JP 2018121494A JP 2018172409 A5 JP2018172409 A5 JP 2018172409A5
Authority
JP
Japan
Prior art keywords
hepe
compositions
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018121494A
Other languages
English (en)
Other versions
JP2018172409A (ja
Filing date
Publication date
Priority claimed from GBGB1301626.6A external-priority patent/GB201301626D0/en
Application filed filed Critical
Publication of JP2018172409A publication Critical patent/JP2018172409A/ja
Publication of JP2018172409A5 publication Critical patent/JP2018172409A5/ja
Pending legal-status Critical Current

Links

JP2018121494A 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法 Pending JP2018172409A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1301626.6 2013-01-30
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015555661A Division JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法

Publications (2)

Publication Number Publication Date
JP2018172409A JP2018172409A (ja) 2018-11-08
JP2018172409A5 true JP2018172409A5 (ja) 2019-05-16

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法

Country Status (27)

Country Link
US (6) US20150224076A1 (ja)
EP (2) EP2762143B1 (ja)
JP (2) JP6363104B2 (ja)
KR (6) KR20230047201A (ja)
CN (2) CN111214464A (ja)
AU (2) AU2014211628B2 (ja)
BR (1) BR112015018270A2 (ja)
CA (1) CA2897343C (ja)
CY (1) CY1117209T1 (ja)
DK (1) DK2762143T3 (ja)
ES (2) ES2564025T3 (ja)
GB (1) GB201301626D0 (ja)
HR (1) HRP20160203T1 (ja)
HU (1) HUE026901T2 (ja)
IL (3) IL239893A (ja)
MX (2) MX364646B (ja)
NZ (1) NZ709803A (ja)
PH (1) PH12015501582B1 (ja)
PL (1) PL2762143T3 (ja)
PT (1) PT2762143E (ja)
RS (1) RS54584B1 (ja)
RU (2) RU2671208C2 (ja)
SG (2) SG11201505457PA (ja)
SI (1) SI2762143T1 (ja)
SM (1) SMT201600069B (ja)
WO (1) WO2014118097A1 (ja)
ZA (2) ZA201505018B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2019110980A (ru) * 2014-01-10 2019-08-26 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド 15−オキソ−epaまたは15−オキソ−dglaを含む組成物、ならびにその作製及び使用方法
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) * 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe
PT3720431T (pt) 2017-12-06 2024-12-05 Basf As Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール.ピー.シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
AU3846801A (en) * 2000-02-16 2001-08-27 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
MXPA03010888A (es) 2001-05-30 2004-02-27 Laxdale Ltd Coenzimas q y acido eicosapentaenoico (epa).
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
CN101043884A (zh) 2004-07-01 2007-09-26 谢彭斯眼科研究公司 用于治疗眼部疾病和病症的组合物和方法
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
WO2008021192A2 (en) 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
EP2143430B1 (en) * 2007-03-30 2015-09-23 Kowa Company, Ltd. Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防/改善・治療薬
JP5523439B2 (ja) * 2009-02-20 2014-06-18 国立大学法人 東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8936803B2 (en) 2011-10-19 2015-01-20 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013082265A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
SG10201701004RA (en) 2012-01-06 2017-04-27 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2858496B9 (en) 2012-05-10 2023-11-29 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
EP4218736A3 (en) 2015-12-18 2023-10-18 Afimmune Limited Compositions comprising 15-hepe

Similar Documents

Publication Publication Date Title
IL291933A (en) Oligonucleotide compositions and methods of use thereof
JP2018172409A5 (ja) 15−hepeを含む組成物および同組成物を使用する方法
EP3823673A4 (en) Anti-cd112r compositions and methods
DK3963021T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåder til anvendelse deraf
IL271025A (en) Multibiotic agents and methods of using the same
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
EP3600325A4 (en) UNIQUE COMPOSITIONS AND PROCESSES
EP3746071A4 (en) GCN2 INHIBITORS AND THEIR USES
EP3746075A4 (en) GCN2 INHIBITORS AND THEIR USES
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL269334A (en) Improved t cell compositions and methods
EP3826638A4 (en) ELAGOLIX SODIUM COMPOSITIONS AND RELATED METHODS
PL3258962T3 (pl) Mieszane kompozycje alergenów i sposoby ich stosowania
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PL3394259T3 (pl) Kompozycje i sposoby zmniejszania ekspresji tau
IL286481A (en) Pyridazinones and methods of use thereof
IL281938A (en) Stable semaglutide compositions and uses thereof
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
MA54143A (fr) Compositions et méthodes
EP3743525A4 (en) PROXIMITY DETECTION METHODS AND COMPOSITIONS
IL276135A (en) Preparations and methods of use
EP3844500A4 (en) RP182 COMPOSITIONS AND METHODS
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
EP3630150A4 (en) Purified anthelmintic compositions and related methods